放射性125I粒子植入治疗中重度癌性疼痛的临床疗效观察

摘要

目的 探讨放射性 125I粒子植入治疗中重度癌性疼痛的临床疗效及安全性.方法 选取80例中重度癌性疼痛患者,采取数字表法随机分为观察组(n=40)和对照组(n=40).对照组给予常规药物治疗,观察组给予放射性 125I粒子植入治疗.比较两组患者疼痛数字评分量表(NRS)、疼痛缓解率、日平均疼痛时间及不良反应.结果 治疗后1 d,两组患者的NRS评分比较差异无统计学意义(P>0.05);治疗后3 d、7 d、14 d、28 d,观察组患者NRS评分明显低于对照组,组间比较差异均具有统计学意义(P<0.05);观察组的疼痛缓解率为90.0%,明显高于对照组的60.0%,组间比较差异有统计学意义(P<0.05);治疗后28 d,观察组日平均疼痛时间为(1.2±0.5) h,明显短于对照组的(3.0 ± 0.4) h,不良反应发生率为2.5%,明显低于对照组的22.5%,组间比较差异均具有统计学意义(P<0.05).结论 放射性125I粒子植入治疗中重度癌性疼痛的效果优于常规药物治疗,且不良反应少.%Objective To evaluate the efficacy and safety of radioactive I125 seed implantation in the treatment of moderate and severe cancer pain. Methods Eighty patients with moderate and severe cancer pain were divided into observation group (n=40) and control group (n=40) according to random number table. The radioactive 125I seed implanta-tion was used in the observation group and routine drug treatment was used in the control group. The numerical rating scale (NRS) score, pain relief rate, average daily pain time and adverse reactions were compared between the two groups. Results The NRS score showed no statistically significant difference between the observation group and the control group after treatment for 1 d (P>0.05), but the NRS score of the observation group was significantly lower than that in the control group after treatment for 3 d, 7 d , 14 d and 28 d (P<0.05). The pain relief rate of the observation group was 90.0%(36/40), significantly higher than 60.0%(24/40) of the control group (P<0.05). After treatment for 28 d, the average daily pain time of the observation group [(1.2 ± 0.5) h] was significantly less than that of the control group [(3.0±0.4) h], P<0.05. The adverse reaction rate of observation group (2.5%) was significantly lower than that of the con-trol group (22.5%), P<0.05. Conclusion Radioactive 125I seed implantation has better efficacy for the treatment of mod-erate and severe cancer pain than conventional drug treatment, with less adverse reactions.